Medicare Enrolled

Dr. David Samimi, MD

Ophthalmology · Los Angeles, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
1513 S GRAND AVE, Los Angeles, CA 90015
2132341000
In practice since 2007 (18 years)
NPI: 1306044102 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Samimi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Samimi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Samimi

Dr. David Samimi is an ophthalmology specialist in Los Angeles, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Samimi performed 6,125 Medicare services across 1,823 unique beneficiaries.

Between the years covered by Open Payments, Dr. Samimi received a total of $2,348 from 15 pharmaceutical and/or device companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Samimi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 16% volume in CA $2,348 industry payments

Medicare Practice Summary

Medicare Utilization ↗
6,125
Medicare services
Top 16% in CA for ophthalmology
1,823
Unique beneficiaries
$37
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~340 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Botox injection (Xeomin), per unit
An injection of incobotulinumtoxin A, a botulinum toxin type A product, administered in a quantity of one unit.
3,990 $4 $6
Eye photography
Photographic imaging of the interior structures of the eye.
710 $21 $59
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
346 $134 $372
Visual field test, limited
A test that measures your side (peripheral) vision. This limited version assesses a restricted portion of your visual field.
219 $25 $95
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
210 $104 $226
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
166 $73 $144
Insertion of probe into nasal tear duct 113 $209 $1,083
Nasal endoscopy
A diagnostic procedure that uses a thin, lighted tube to examine the inside of the nasal passages.
112 $94 $488
Chemical nerve block for facial paralysis
Injection of a chemical agent to paralyze specific nerves or muscles on the side of the face.
78 $168 $700
Eyelid margin reconstruction
Surgical repair to restore the structure and function of the eyelid margin.
36 $512 $1,608
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
31 $91 $264
Upper eyelid muscle shortening or advancement
A surgical procedure to shorten or advance the upper eyelid muscle. It is performed to correct drooping or paralysis of the eyelid.
29 $551 $2,323
Eyelid growth removal
A procedure to remove a growth from the eyelid.
26 $201 $771
Eyelid lining repair with graft from external eye
This procedure repairs the inner lining of the eyelid using tissue grafted from another part of the eye.
17 $379 $1,952
Nasal tear duct probing with tube or stent insertion
A procedure to open a blocked tear duct by probing the area and inserting a tube or stent to maintain drainage.
17 $102 $694
Nasal tear duct probing
A procedure to examine and clear the tear ducts in the nose. It helps restore normal drainage of tears from the eye.
14 $80 $411
Removal of excessive skin and fat of upper eyelid 11 $826 $3,408
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.3% high complexity
67.0% medium
32.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$2,348
Total received (2018-2024)
Avg $335/year across 7 years
Top 39% in CA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
15
Companies
25
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,348 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$824
2023
$226
2022
$236
2021
$167
2020
$142
2019
$376
2018
$377

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$413
Amgen Inc.
$150
Integra LifeSciences Corporation
$135
Bausch & Lomb Americas Inc.
$125
Top 3 companies account for 84.8% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$649
Allergan Inc.
$249
Galderma Laboratories, L.P.
$216
Shire North American Group Inc
$156
Amgen Inc.
$150
AbbVie Inc.
$148
Allergan, Inc.
$145
Integra LifeSciences Corporation
$135
Novartis Pharmaceuticals Corporation
$134
Bausch & Lomb Americas Inc.
$125
Stryker Corporation
$84
Merz North America, Inc.
$77
Horizon Therapeutics plc
$40
Janssen Biotech, Inc.
$22
Carl Zeiss Meditec, Inc.
$17
Top 3 companies account for 47.4% of all-time payments
Associated products mentioned in payments ›
BOTOX · Integra · MIEBO · None Specified · SPIROX - LATERA · STELARA · TEPEZZA · VUITY · XIIDRA · Xeomin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an ophthalmology specialist in Los Angeles?
Compare ophthalmologists in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists within 10 mi
787
Per 100K population
8.0
County median income
$87,760
Nearest hospital
CALIFORNIA HOSPITAL MEDICAL CENTER LA
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Samimi is a mixed practice specialist, with above-average Medicare volume (top 16% in CA), with low-engagement industry engagement, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Samimi experienced with botox injection (xeomin), per unit?
Based on Medicare claims data, Dr. Samimi performed 3,990 botox injection (xeomin), per unit services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Samimi receive payments from pharmaceutical companies?
Yes. Dr. Samimi received a total of $2,348 from 15 companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Samimi's costs compare to other ophthalmologists in Los Angeles?
Dr. Samimi's average Medicare payment per service is $37. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Samimi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →